Please login to the form below

Not currently logged in
Email:
Password:

Lartruvo

This page shows the latest Lartruvo news and features for those working in and with pharma, biotech and healthcare.

Lilly bags EU approval for cancer treatment Lartruvo

Lilly bags EU approval for cancer treatment Lartruvo

Lilly bags EU approval for cancer treatment Lartruvo. Licensed for use with doxorubicin for soft tissue sarcoma patients. ... Until then, Lartruvo will be subject to an annual safety review by the CHMP.

Latest news

  • Lilly snags first approval for sarcoma drug Lartruvo Lilly snags first approval for sarcoma drug Lartruvo

    Lilly snags first approval for sarcoma drug Lartruvo. Granted accelerated approval by the FDA becoming first front-line STS therapy for 40 years. ... Eli Lilly has picked up its first green light for its soft tissue sarcoma (STS) therapy Lartruvo, ending

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    Lilly closes on first approval for sarcoma drug Lartruvo. Orphan drug improved patient survival time by almost 12 months in phase II trial. ... It is thought that by binding to the receptor Lartruvo can slow down tumour growth.

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics